SRXH

NORTH PALM BEACH, Fla., Oct. 08, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE:SRXH) (the "Company" or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced an initial investment of $2.5 million to seed a newly formed multi-strategy trading platform fund. The new platform was established as a strategic joint venture between SRX's internal EMJX division and 5T Trading. "Our investment in this multi-strategy trading platform aligns perfectly with SRX's mandate to invest in high-conviction, strategic assets," said Kent Cunningham, Chief Executive Officer of SRX Glob

SPV, CERO 1236, to raise capital directly into subsidiary and not dilute existing SRX Global shareholders Proposed acquisition expected to accelerate development of CERo's lead product candidate, CER-1236, for hematologic malignancies NORTH PALM BEACH, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE:SRXH) (the "Company" or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that it has entered into definitive purchase agreement under which CERo Therapeutics, the operating subsidiary of CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo Holdings"

8-K - SRX Global Inc. (0001471727) (Filer)

SRX to dividend ETF holdings to shareholders  Initial ETF to feature an actively managed digital asset hedging strategy powered by EMJX’s proprietary AI technology NORTH PALM BEACH, Fla., Oct. 06, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE:SRXH) (the "Company" or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced a $1.5 million commitment to launch a new family of actively managed Exchange Traded Funds (ETFs) through its EMJX platform, marking the first step in bringing EMJX’s proprietary AI-driven investment intelligence to the broader investing public.

8-K - SRX Global Inc. (0001471727) (Filer)

NORTH PALM BEACH, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE:SRXH) (the "Company" or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced an update to shareholders on the liquidation of portfolio holdings Vistagen Therapeutics (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company, and Greenland Mines (NASDAQ:GRML), a critical and precious minerals development company. Additionally, the Company has added an investment in Onconetix Inc. (NASDAQ:ONCO). Onconetix has previously announced an agreement to acquire Realbotix LLC. Realbotix ut

NORTH PALM BEACH, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE:SRXH) (the "Company" or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that SRX Global’s CEO, Kent Cunningham, and President, EMJX Platform and Head of Asset Management, Eric Jackson, will present at the Webull Corporate Connect Series Fintech Investment Webinar, a live investor webinar hosted on the Webull platform, on September 30, 2026. Webull Corporate Connect Series Fintech Investment WebinarDate: Tuesday, September 30, 2026Time: 1:00 p.m. ETSpeakers: Kent Cunningham, CEO,

8-K - SRX Global Inc. (0001471727) (Filer)

NORTH PALM BEACH, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE:SRXH) (the "Company" or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today is providing shareholders with an update on its portfolio company ARMR Sciences ("ARMR"), a clinical-stage biodefense company developing a platform of medical countermeasures against synthetic drugs, such as fentanyl, from its CEO, Collin Gage. ARMR recently announced its lead product, ARMR-100, successfully generated an anti-fentanyl immune response in humans and showed favorable safety data. This marks a critical mil

8-K - SRX Global Inc. (0001471727) (Filer)

NORTH PALM BEACH, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE:SRXH) (the "Company" or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that it has purchased senior secured debt in CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo Holdings" and, together with CERo Therapeutics, "CERo"), an innovative cellular immunotherapy company advancing next generation engineered T cell therapeutics that employ phagocytic mechanisms. The investment is expected to provide CERo with additional capital to accelerate the advancement of its clinical programs.

8-K - SRX Global Inc. (0001471727) (Filer)

8-K - SRX Global Inc. (0001471727) (Filer)

10-Q - SRX Global Inc. (0001471727) (Filer)

Net Asset Value ("NAV") of $62.9 million, or $3.22 per Common Share, Exceeding Preliminary Estimate of $3.07 per Share1 Ended the Quarter with $36.7 million of Cash, Cash Equivalents and Restricted Cash, $65.2 million in Current Assets, and $2.4 million in Total Liabilities, With No Debt Outstanding Adjusted EBITDA Loss Improved 35% year over year to $1.6 million4 Strengthened Halo Operations, Exiting the Quarter with 98% Fill Rates and Record Prime Day Performance NORTH PALM BEACH, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE:SRXH) (the "Company" or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-convictio

NORTH PALM BEACH, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE:SRXH) (the "Company", or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that it plans to host a conference call and report its financial results for the fiscal third quarter ended June 30, 2026, on Thursday, August 13, 2026. Conference Call DetailsEvent:SRX Global Inc. Fiscal Third Quarter 2026 Conference CallDate:Thursday, August 13, 2026Time:4:30 p.m. ETWebcast:https://www.srxglobalinc.com/news-events/ir-calendar   For interested individuals unable to join the call, a link to th

NORTH PALM BEACH, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE:SRXH) (the "Company", or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that it has acquired a stake in Vistagen Therapeutics, Inc. (Vistagen) (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. The Company views Vistagen shares as undervalued and welcomes constructive engagement with its leadership team and Board of Direc

NORTH PALM BEACH, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE:SRXH) (the "Company", or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that its portfolio company Smartkem, Inc. (NASDAQ:SMTK), a leader in advanced materials, will merge with Ferrox Critical Minerals, strengthening its critical minerals sourcing. The business combination will be subject to customary closing conditions, including the approval of Smartkem and Ferrox shareholders. SRX previously announced that it acquired 4.99% of Smartkem, Inc. through a shelf take down and purc

NORTH PALM BEACH, Fla., July 30, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE:SRXH) (the "Company", or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that it acquired shares in the initial public offering of Jersey Mike’s, a leading fast-casual restaurant franchisor with more than 3,300 locations across the United States and Canada, which priced its Class A common shares at $23.00 per share yesterday at a total valuation of $1 billion and began trading on the New York Stock Exchange today under the ticker JMKE. About SRX Global Inc. SRX Global is an AI-dr

8-K/A - SRX Global Inc. (0001471727) (Filer)

8-K - SRX Global Inc. (0001471727) (Filer)

8-K - SRX Global Inc. (0001471727) (Filer)

424B3 - SRX Global Inc. (0001471727) (Filer)

424B3 - SRX Global Inc. (0001471727) (Filer)

8-K - SRX Global Inc. (0001471727) (Filer)